{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:47:01Z","timestamp":1760240821310,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:00:00Z","timestamp":1569196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health and Welfare","award":["HO15C0003"],"award-info":[{"award-number":["HO15C0003"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>For optimum radioimmunotherapy (RIT), deep penetration and uniform distribution into the tumor core is important. The solid tumor microenvironment, consisting of a highly fibrotic or desmoplastic tumor, abnormal tumor vasculature, high fluid pressure, and the absence of fluid lymphatics, limits the distribution of monoclonal antibodies mAbs to the tumor core. To investigate the optimal rationale for therapeutic mAbs administration and the microdistribution of mAbs, single and serial fractional dosage regimens of Cu-64-trastuzumab (TRZ) with paclitaxel were evaluated. Groups of nude mice were inoculated with gastric cancer cell line NCI-N87 tumor cells. When the tumor size reached 200 \u00b1 20 mm3, the mice were divided into two groups for injection of Alexa-647-TRZ. One group (n = 5) was injected with 15 mg\/kg in a single dose (SD), and the other group (n = 5) with two doses of 7.5 mg\/kg (fractionated dose (FD)). In both cases, the injections were done intravenously in combination with intraperitoneal paclitaxel either as a SD of 70 mg\/kg or fractionated into two doses of 40 and 30 mg\/kg. Tumors were harvested, flash frozen, and sectioned (8 \u00b5m) five days after Alexa-647-TRZ injection. Rhodamine lectin (rhodamine-labeled Ricinus communis agglutinin I, 1 mg in 0.2 mL of phosphate-buffered saline (PBS)) was intravenously injected to delineate the functional vessel for a wait time of 5 min before animal euthanization. Microscopic images were acquired with an IN Cell Analyzer. The amount of TRZ that penetrated the tumor surface and the tumor vessel was calculated by area under the curve (AUC) analysis. For RIT efficacy (n = 21), Cu-64-TRZ was injected following the same dose schedule to observe tumor volume and survival ratio for 30 days. The SD and FD regimens of Alexa-647-TRZ were observed to have no significant difference in penetration of mAbs from the tumor edge and vessel, nor was the total accumulation across the whole tumor tissue significantly different. Additionally, the SD and FD regimens of Cu-64-TRZ were not proven to be significantly efficacious. Our study reveals that SD and FD in a treatment design with Cu-64-TRZ and paclitaxel shows no significant difference in therapeutic efficacy on tumor growth inhibition in vivo in mice bearing human gastric cancer xenografts overexpressing HER2 antigen.<\/jats:p>","DOI":"10.3390\/ijms20194708","type":"journal-article","created":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T11:02:00Z","timestamp":1569236520000},"page":"4708","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison between Fractionated Dose and Single Dose of Cu-64 Trastuzumab Therapy in the NCI-N87 Gastric Cancer Mouse Model"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1418-1047","authenticated-orcid":false,"given":"Javeria","family":"Zaheer","sequence":"first","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"},{"name":"Radiological and Medico-Oncological Sciences, University of Science and Technology (UST), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6990-3900","authenticated-orcid":false,"given":"Hyeongi","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Jin","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Moo","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-9538","authenticated-orcid":false,"given":"Jin Su","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of RI Application, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"},{"name":"Radiological and Medico-Oncological Sciences, University of Science and Technology (UST), 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1088\/0031-9155\/41\/10\/011","article-title":"Treatment planning for radio-immunotherapy","volume":"41","author":"Erdi","year":"1996","journal-title":"Phys. Med. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc903","article-title":"Ligand-targeted therapeutics in anticancer therapy","volume":"2","author":"Allen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","first-page":"141S","article-title":"Current status of therapy of solid tumors","volume":"46","author":"Jhanwar","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_4","first-page":"57","article-title":"Factors determining antibody distribution in tumors","volume":"29","author":"Thurber","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure\u2014An obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Heine, M., Freund, B., Nielsen, P., Jung, C., Reimer, R., Hohenberg, H., Zangemeister-Wittke, U., Wester, H.J., Luers, G.H., and Schumacher, U. (2012). High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0036258"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1002\/cncr.27592","article-title":"Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial","volume":"118","author":"Ocean","year":"2012","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.2005.03.8471","article-title":"Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy","volume":"24","author":"Goldenberg","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2967\/jnumed.112.110700","article-title":"Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein","volume":"54","author":"Orlova","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-12-0336","article-title":"A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity","volume":"12","author":"Weldon","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1158\/0008-5472.CAN-06-2495","article-title":"Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma","volume":"67","author":"Du","year":"2007","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lee, S., Kim, H., Kang, Y.-r., Kim, H., Kim, J.Y., Lee, Y.-J., Kim, J.M., and Kim, J.S. (2019). Selection Criteria for Determination of Optimal Reconstruction Method for Cu-64 Trastuzumab Dosimetry on Siemens Inveon PET Scanner. J. Clin. Med., 8.","DOI":"10.3390\/jcm8040512"},{"key":"ref_14","first-page":"1322","article-title":"Effect of mAb B3 with paclitaxel doses on accumulation and penetration of B3 into tumor","volume":"54","author":"Kim","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jconrel.2012.06.025","article-title":"Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors","volume":"162","author":"Wang","year":"2012","journal-title":"J. Control Release"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.nucmedbio.2011.10.020","article-title":"Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab","volume":"39","author":"Jang","year":"2012","journal-title":"Nucl. Med. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1349-7006.2009.01423.x","article-title":"Semiquantitative assessment of the microdistribution of fluorescence-labeled monoclonal antibody in small peritoneal disseminations of ovarian cancer","volume":"101","author":"Kosaka","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2967\/jnumed.107.046888","article-title":"Pulsed high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice","volume":"49","author":"Khaibullina","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res."},{"key":"ref_21","first-page":"538","article-title":"Single-Dose Versus Fractionated Radioimmunotherapy: Model Comparisons for Uniform Tumor Dosimetry","volume":"41","author":"Joseph","year":"2000","journal-title":"J. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/cncr.10304","article-title":"Rationales, evidence, and design considerations for fractionated radioimmunotherapy","volume":"94","author":"DeNardo","year":"2002","journal-title":"Cancer"},{"key":"ref_23","first-page":"5881s","article-title":"Fractionated Radioimmunotherapy of Human Colon Carcinoma Xenografts with 131I-labeled Monoclonal Antibody CC49","volume":"55","author":"Buchsbaum","year":"1995","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7150\/thno.16647","article-title":"Antigen-responsive molecular sensor enables real-time tumor-specific imaging","volume":"7","author":"Kim","year":"2017","journal-title":"Theranostics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/jlcr.3287","article-title":"64Cu-labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice","volume":"58","author":"Nielsen","year":"2015","journal-title":"J. Labelled Comp. Radiopharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2967\/jnumed.118.210294","article-title":"Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies","volume":"60","author":"Woo","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"P07001","DOI":"10.1088\/1748-0221\/10\/07\/P07001","article-title":"Tumor dosimetry for 131I trastuzumab therapy in a Her2+ NCI N87 xenograft mouse model using the Siemens SYMBIA E gamma camera with a pinhole collimator","volume":"10","author":"Lee","year":"2015","journal-title":"J. Instrum."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13550-015-0082-6","article-title":"64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients","volume":"5","author":"Kurihara","year":"2015","journal-title":"EJNMMI Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1073\/pnas.78.9.5608","article-title":"Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores","volume":"78","author":"Geuens","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/19\/4708\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:23:12Z","timestamp":1760188992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/19\/4708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,23]]},"references-count":29,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["ijms20194708"],"URL":"https:\/\/doi.org\/10.3390\/ijms20194708","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2019,9,23]]}}}